The therapeutic effect of Midodrine in patients with refractory gastro esophageal reflux disease: a randomized double-blind clinical trial

Shiraz University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2018年2月22日

试验速览

暂无简介。

•age more than 18 and below 65; presence of at least one symptom compatible compatible with GERD including epigastric or retrosternal burning sensation, regurgitation, or acid taste in the mouth; lack of response to the proper consumption of pantoprazole 40 mg twice daily for a minimum of one month.
•Exclusion criteria: dominant symptom of dysphagia; history of surgery of the upper GI system; concomitant GI diseases such as NET, malignancy, peptic ulcer disease; presence of other diseases like hypertension, cardiovascular diseases, history of urinary retention, hypersensitivity to midodrine, leg cramp or vascular insufficiency in the abdomen or legs, acute or chronic renal dysfunction with GFR < 50%, thyroid disease, diabetes mellitus, pheochromocytoma, liver cirrhosis, asthma or COPD; use of medications affecting lower esophageal sphincter such as theophylline, beta blockers, NSAIDs, steroids, bronchodilators; antihistamine taking; pregnancy and lactation; psychiatric disorders or use of antidepressive agents; current smoker; alcohol consumption; use of narcotics or illicit drugs; history of glaucoma.

发起方